Supplementary Table 3 A sampling of the recent literature, along with all of the available MET inhibition resistance literature, highlighting the selection methodologies employed for idenfiying spontaneous acquired resistance with cell culture models.
Reference Selection Agent Approach Sakatani A, et al., Carcinogenesis. 2018 5-FU ramp-up selection Nie H, et al., Biomedicine & Pharmacotherapy. 2019 Afatinib ramp-up selection Kim S, et al., Cancer Research and Treatment. 2018 Capmatinib ramp-up selection Chen H, et al., OncoTargets and Therapy. 2018 Ceritinib ramp-up selection Wu W, et al., Biochemical and Biophysical Research Communications. 2017 Cisplatin ramp-up selection McDermott U, et al., Cancer Research. 2010 Crizotinib ramp-up selection Kim S-J, et al., Cancer Research and Treatment. 2018 Crizotinib or Ceritinib or Alectinib ramp-up selection Shintani T, et al., Oncotarget. 2018 Erlotinib ramp-up selection Choi K-M, et al., Biochemical and Biophysical Research Communications. 2018 GDC-0623 ramp-up selection Wang L, et al., Journal of Cancer Research and Clinical Oncology. 2019 Gefitinib ramp-up selection Wu S-G, et al., Cancers. 2019 Gefitinib or Erlotinib ramp-up selection Shah KN, et al., Nature Medicine. 2019 Osimertinib or Rociletinib ramp-up selection Lee NV, et al., PLoS One. 2012 PF-0461903 ramp-up selection Qi J, et al., Cancer Research. 2011 PHA-665752 ramp-up selection Cepero V, et al., Cancer Research. 2010 PHA-665752 ramp-up selection Gimenez-Xavier P, et al., Molecular Cancer Therapeutics. 2017 PHA-665752 ramp-up selection Wang J, et al., Cancer Letters. 2019 Regorafenib ramp-up selection Nakatani K, et al., Molecular Cancer Therapeutics. 2018 Rociletinib or Osimertinib ramp-up selection Kim B, et al., Oncogene. 2015 SAIT301 ramp-up selection Lai H-H, et al., Molecular Oncology. 2019 Sorafenib ramp-up selection Scaltriti M, et al., PNAS. 2011 Trastuzumab ramp-up selection Larribère L, et al., Cancers. 2018 Vemurafenib ramp-up selection
Namba K, et al., Molecular Cancer Research. 2018 Osimertinib ramp-up selection; intermittent hard-hit selection
Mumin NH, et al., BMC Cancer. 2019 Ganetespib hard-hit selection Widatalla SE, et al., Carcinogenesis. 2018 Lapatinib hard-hit selection Laurenzana A, et al., EBioMedicine. 2019 Vemurafenib hard-hit selection
Mologni L, et al., Neoplasia. 2018 Vemurafenib hard-hit with additional ramp-up selection
Nakata A, et al., Scientific Reports. 2015 Gefitinib soft-hit selection